

Interim Considerations:

Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites Summary



Anaphylaxis is an acute and potentially life-threatening serious allergic reaction. Severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine or any component of the COVID-19 vaccine listed in the prescribing information is a contraindication to vaccination. A history severe allergic reaction to any other vaccine or injectable therapy is a precaution to vaccination.



Appropriate medical treatment for severe allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine.

» Recommended observation period following COVID-19 vaccination

CDC recommends the following observation periods after vaccination:

- Persons with a history of anaphylaxis (due to any cause): 30 minutes
- All other persons: 15 minutes

» Early recognition of anaphylaxis

Because anaphylaxis requires immediate treatment, diagnosis is primarily made based on recognition of clinical signs and symptoms, including:

- Respiratory: sensation of throat closing, high-pitched sound while breathing, shortness of breath, wheeze, cough
- Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain
- Cardiovascular: dizziness, fainting, abnormally fast heart rate, abnormally low blood pressure
- Skin/mucosal: generalized hives, itching, or swelling of lips, face, throat

Symptoms are considered generalized if there are generalized hives and/or more than one body system is involved. If a patient develops itching and swelling confined to the injection site, the patient should be observed closely for the development of generalized symptoms (beyond the recommended observation periods, if necessary). If symptoms are generalized, epinephrine should be administered as soon as possible, and emergency medical services should be sought.

» Medications and supplies for assessing and managing anaphylaxis

- COVID-19 vaccines will likely be administered in a wide variety of clinical settings that will differ in terms of usual on-hand human and material resources to manage anaphylaxis. The following medications and supplies, listed below, are important for evaluating and managing of anaphylaxis and are recommended for COVID-19 vaccination sites.

A clinical provider with access to the emergency equipment should be immediately available to assess and manage anaphylaxis.

Should be available at all sites	If feasible, include at sites (not required)
Epinephrine prefilled syringe or autoinjector*	Pulse oximeter
H1 antihistamine (e.g., diphenhydramine)†	Oxygen
Blood pressure cuff	Bronchodilator (e.g., albuterol)
Stethoscope	H2 antihistamine (e.g., famotidine, cimetidine)
Timing device to assess pulse	Intravenous fluids
	Intubation kit
	Adult-sized pocket mask with one-way valve (also known as cardiopulmonary resuscitation (CPR) mask)

* COVID-19 vaccination sites should have at least 3 doses of epinephrine on hand at any given time.

† Antihistamines may be given as adjunctive treatment but should not be used as initial or sole treatment for anaphylaxis. Additionally, caution should be used if oral medications are administered to persons with impending airway obstruction.

Interim Considerations:

Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites Summary



» Management of anaphylaxis at a COVID-19 vaccination site.

If anaphylaxis is suspected, take the following steps:

- Rapidly assess airway, breathing, circulation, and mentation (mental activity).
- Call for emergency medical services.
- Place the patient in a supine position (face up), with feet elevated, unless upper airway obstruction is present or the patient is vomiting.
- Epinephrine (1 mg/ml aqueous solution [1:1000 dilution]) is the first-line treatment for anaphylaxis and should be administered immediately.
 - In adults, administer a 0.3 mg intramuscular dose using a premeasured or prefilled syringe, or an autoinjector in the mid-outer thigh.
 - The maximum adult dose is 0.5 mg per dose.
 - Epinephrine dose may be repeated every 5–15 minutes (or earlier) as needed to control symptoms while waiting for emergency medical services.
 - Because of the acute, life-threatening nature of anaphylaxis, there are no contraindications to epinephrine administration.

Antihistamines (e.g., H1 or H2 antihistamines) and bronchodilators do not treat airway obstruction or hypotension, and are not first-line treatments for anaphylaxis. However, they can help provide relief for hives and itching (antihistamines) or symptoms of respiratory distress (bronchodilators) but should only be administered after epinephrine in a patient with anaphylaxis.

Because anaphylaxis may recur after patients begin to recover, monitoring in a medical facility for several hours is advised, even after complete resolution of symptoms and signs.

» Patient counseling

Patients who experience anaphylaxis after the first dose of COVID-19 vaccination should be instructed not to receive additional doses. In addition, patients should be referred to an allergist-immunologist for appropriate work-up and additional counseling.

» Reporting of anaphylaxis

Any adverse events that occur in a recipient following COVID-19 vaccination, including anaphylaxis, are required to be reported to the Vaccine Adverse Event Reporting System (VAERS) under Emergency Use Authorization. Information on how to submit a report to VAERS is available at <https://vaers.hhs.gov> or by calling 1-800-822-7967.

Additional resources

ACIP Rapid overview: Emergent management of anaphylaxis in infants and children
<https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html#t-01>

ACIP Rapid overview: Emergent management of anaphylaxis in adults
<https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html#t-02>

Immunization Action Coalition: Medical Management of Vaccine Reactions in Adults
<https://www.immunize.org/catg.d/p3082.pdf>

Pfizer-BioNTech COVID-19 Vaccine prescribing information
[this https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)

Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites
<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html>

Moderna COVID-19 Vaccine prescribing information
<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine>